Medical Mystery: The Man Who Got Weaker When He Started Training

A 43-year-old man starts exercising and ends up in the ER with a CK over 100x the upper limit of normal. His doctor says it’s from training. We don’t think so. In this episode, Dr. Jordan Feigenbaum and Dr. Austin Baraki walk through the full case — history, labs, diagnosis, and what actually went wrong — then break down the mechanisms behind the answer, the nocebo research, and what the brand-new 2026 guidelines mean for the 40 million Americans on a drug class you’ve definitely heard of.
We also cover the STOMP trial (do statins actually impair strength gains?), the SAMSON trial (how much of statin intolerance is nocebo?), the difference between myalgia, myositis, and rhabdomyolysis, Austin’s clinical approach to a patient whose strength is declining on a statin, and the treatment escalation pathway for statin-intolerant patients including bempedoic acid, PCSK9 inhibitors, and inclisiran. Plus, where GLP-1 receptor agonists like tirzepatide fit into the cardiovascular risk picture.
Timestamps
0:00 — A 43-year-old man is getting weaker, not stronger
2:09 — Taking the history: Medications, lifestyle, and red flags
12:53 — The labs come back: CK at 18,979
16:05 — Metabolic syndrome and the modern treatment approach
23:15 — Rhabdomyolysis: What it is and why it’s dangerous
29:50 — Final diagnosis and what went wrong with the medications
37:15 — 2026 ACC lipid guidelines: What changed
40:32 — Three mechanisms: How statins affect muscle
47:02 — The nocebo effect and the SAMSON trial
54:17 — Do statins impair training? The STOMP trial
1:00:30 — Who’s at highest risk for statin muscle problems
1:07:36 — What happened to the patient and options if this is you
1:14:12 — Five takeaways
Five Takeaway
Statin myopathy is real but relatively uncommon. The excess symptom rate above placebo is roughly 1–5% in controlled trials. But in exercising patients, especially on combination therapy, the risk can be higher.
There are three proposed mechanisms: reduced energy production from CoQ10 depletion, compromised muscle cell membranes from isoprenoid loss, and accelerated protein breakdown from calcium leak via the ryanodine receptor. Exercise amplifies all three, but the vast majority of people compensate.
If you’re on a statin and your strength is going down, talk to your doctor before stopping the medication or changing your training. A CK test can help separate a drug problem from a programming problem
The 2026 ACC guidelines list vigorous exercise as a risk factor for statin-associated muscle symptoms for the first time. They also provide statin-intolerant patients a clear escalation pathway: bempedoic acid, ezetimibe, PCSK9 inhibitors, and more.
Lower is better for LDL. There’s a 33% relative reduction in cardiovascular events at <55 vs. 70 mg/dL. Lower for longer. Healthy lifestyle changes plus effective lipid-lowering therapy are among the best things you can do for cardiovascular risk.
Next Steps
For evidence-based resistance training programs: barbellmedicine.com/training-programs
For individualized training consultation: barbellmedicine.com/coaching
Explore our full library of articles on health and performance: barbellmedicine.com/resources
To consult with Drs. Baraki or Feigenbaum email us at [email protected]
To support us and get ad free listening, plus special product discounts, and exclusive content, go to supercast.barbellmedicine.com
Resources
Training Plateau Action Plan (free):
https://www.barbellmedicine.com/training-plateau-action-plan/
Fish oil episode:
https://open.spotify.com/episode/4kRtXZBMZWKkZPDdIKpu1S
Lp(a): https://www.barbellmedicine.com/blog/lipoprotein-a-testing-and-treatment/
Guidelines
Blumenthal RS, Morris PB, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423
Case
László A, et al. Exercise and Statin-Fibrate Combination Therapy-Caused Myopathy. BMC Research Notes. 2013;6:52. https://pubmed.ncbi.nlm.nih.gov/23388500/
LDL Targets
L...